

VASTox plc
(“VASTox” or “the Company”)

**MAJOR PHARMACEUTICAL COMPANIES PRESENT VASTOX DATA AT
LEADING INTERNATIONAL CONFERENCE**

Oxford, UK, 27 March 2007 – VASTox plc (AIM: VOX) today announced that Roche, Bayer-Schering and Merz will present scientific data gathered using VASTox’s proprietary zebrafish technology platform at the Society of Toxicity Annual Meeting being held in Charlotte, North Carolina between the 25-29 March 2007.

In 2006, VASTox entered into a joint pilot study with the three European pharmaceutical companies to test if a known set of compounds were teratogenic and would therefore cause malformations in a developing embryo. Using VASTox’s proprietary ‘vivo™’ predictive toxicology platform, the compounds were blind-screened in zebrafish with the results proving to be highly predictive for this toxic effect. The results from this study will be displayed during a poster symposium at the meeting.

The Society of Toxicology Annual Meeting is the largest toxicology meeting and exhibition in the world, attracting approximately 6,000 scientists from industry, academia and government. The data being presented at the conference will allow VASTox to highlight to a global audience its innovative technology platform, which has the potential to reduce failure rates and cost in drug discovery programmes.

Following this successful pilot study, VASTox is developing plans to expand the original collaboration to include additional leading pharmaceutical companies.

Steven Lee, PhD, CEO, commented: “The completion of the successful pilot study with these leading pharmaceutical companies provides further industry validation of the benefits our world-leading zebrafish technology platform brings to drug discovery programmes. The use of zebrafish within drug discovery has significant potential to both reduce the cost and attrition rates in drug discovery and also reduce the number of higher animal models used in regulatory testing.”

- ends -

For more information, please contact:

VASTox

Steven Lee, PhD, Chief Executive Officer
Darren Millington, Chief Financial Officer

Tel: +44 (0)1235 443951

Citigate Dewe Rogerson

Mark Swallow / David Dible / Valerie Auffray

Tel: +44 (0)207 638 9571

About VASTox's zebrafish platform

VASTox's zebrafish (*Danio rerio*) technology platform allows high-volume, high-content screening of small molecule drug candidates. This approach generates *in vivo* data, which can be used to determine key characteristics of potential drug candidates. These data are highly predictive of efficacy and toxicity in humans, reducing the risk of failure in discovery programmes, while having the potential to dramatically decrease the time and cost of drug discovery and development.

VASTox has developed a wide range of validated toxicology screens, the 'vivo™' screening platform, to assess compound safety and potential side effects. These include:

- Acute toxicity
- Cardiotoxicity
- Hepatotoxicity
- Myelotoxicity
- Embryotoxicity & Teratogenicity

About VASTox plc

VASTox is a leading UK biotechnology company that discovers and develops proprietary new drugs. The Company's internal drug development programmes are underpinned by its advanced chemistry and drug screening (chemical genomics) technology platforms, which it also provides on a collaborative or fee-for-service basis to the pharmaceutical industry.

VASTox has a broad range of drug discovery programmes in the clinical, pre-clinical and discovery stages of development, which target serious diseases with a high unmet medical need. These therapeutic areas include neuro-disorders (neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases, oncology and regenerative medicines.

VASTox's in-house drug development capabilities combine world-class expertise in both medicinal and carbohydrate chemistry with high-volume, high-content screening using its proprietary zebrafish and fruitfly technologies (chemical genomics). These whole organism screens have the potential to dramatically decrease the time and cost of drug discovery and development by delivering data that are highly predictive of the efficacy and toxicity of potential drug compounds in humans.

The company listed on the AIM market of the London Stock Exchange in October 2004 – symbol: VOX

Further information about the company is available at www.vastox.com

This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections.

Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include [factors included in this presentation] and regional, national, global political, economic, business, competitive, market and regulatory conditions.